Find information on thousands of medical conditions and prescription drugs.

Ichthyosis vulgaris

Ichthyosis vulgaris is a skin disorder causing dry, scaly skin. more...

Home
Diseases
A
B
C
D
E
F
G
H
I
ICF syndrome
Ichthyophobia
Ichthyosis vulgaris
Idiopathic...
Imperforate anus
Inborn error of metabolism
Incontinentia pigmenti
Infant respiratory...
Infantile spinal muscular...
Infective endocarditis
Inflammatory breast cancer
Influenza
Inguinal hernia
Insulinoma
Interstitial cystitis
Iodine deficiency
Iridocyclitis
Iritis
Irritable bowel syndrome
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Medicines

It is the most common form of ichthyosis, affecting around 1 in 300 people. For this reason it is known as common ichthyosis. It is also referred to as fish skin disease on account of its appearance.

It is overwhelmingly a dominant inherited disease, although a very rare variant, acquired ichthyosis vulgaris, is not inherited.

The symptoms of the inherited condition manifest themselves at around four years old. The symptoms will often improve with age, although they may grow more severe again in old age.

The acquired variant usually becomes evident during adulthood.

The condition is not life-threatening; the impact on the patient is generally restricted to mild itching and the social impact of having unusual-looking skin.

Read more at Wikipedia.org


[List your site here Free!]


Taro Receives Approval for Ammonium Lactate Cream, 12% ANDA
From Business Wire, 4/10/03

Business Editors/Health/Medical Writers

HAWTHORNE, N.Y.--(BUSINESS WIRE)--April 10, 2003

Taro Pharmaceutical Industries Ltd. (Nasdaq/NMS: TARO) reported today that its U.S. affiliate has received approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for ammonium lactate cream, 12%.

Taro's ammonium lactate cream is bioequivalent to Bristol-Myers Squibb's Lac-Hydrin(R) cream. Ammonium lactate cream is a prescription product used for the treatment of dry, scaly skin (xerosis) and ichthyosis vulgaris and for temporary relief of itching associated with these conditions. According to industry sources, 2002 U.S. sales of ammonium lactate cream products were approximately $34.5 million.

"Ammonium lactate cream gives physicians and patients an affordable option in treating skin disorders such as xerosis and ichthyosis vulgaris," said Barrie Levitt, M.D., Chairman of the Company. "This new product further enhances Taro's position as a leading supplier of topical dermatological products."

Currently, Taro has 23 filings at the FDA: 21 ANDAs, including one tentative approval, one unique supplemental ANDA, and a New Drug Application related to the Company's NonSpil(TM) liquid drug delivery system. In addition, the Company has multiple regulatory filings in Canada, Israel and other countries around the world.

Taro is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products.

For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com.

Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Although Taro Pharmaceutical Industries Ltd. believes the expectations reflected in such forward-looking statements to be based on reasonable assumptions, it can give no assurance that its expectations will be attained. Such forward- looking statements may include, but are not limited to, statements regarding production and marketing of Taro's ammonium lactate cream, 12%. Factors that could cause actual results to differ include industry and market conditions, slower than anticipated penetration of new markets, marketplace acceptance of Taro's ammonium lactate cream, 12%, the future size of the market for this product, changes in the Company's financial position, regulatory actions, and other risks detailed from time to time in the Company's SEC reports, including its 2001 Annual Report on Form 20-F.

COPYRIGHT 2003 Business Wire
COPYRIGHT 2003 Gale Group

Return to Ichthyosis vulgaris
Home Contact Resources Exchange Links ebay